Safety and effectiveness of Rivaroxaban, Dabigatran and Apixaban in patients with non-valvular atrial fibrillation for stroke prophylaxis
Abstract Background Atrial fibrillation is the most common arrhythmia that causes an increased risk of thromboembolism. We aimed to evaluate stroke and major bleeding risk in patients with atrial fibrillation using rivaroxaban, apixaban, dabigatran and the effects of using antiplatelet, atorvastatin...
Saved in:
| Main Authors: | Ceyda Tanoğlu, Alevtina Ersoy |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-025-04306-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01) -
HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
by: S. V. Moiseev
Published: (2015-12-01) -
Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01) -
Plasma levels of direct Xa inhibitors apixaban and rivaroxaban in patients with venous thromboembolism in clinical practice
by: I. Paskaleva, et al.
Published: (2025-05-01) -
Predictive thresholds of peak and trough anti-Xa levels for bleeding risk in rivaroxaban-treated nonvalvular atrial fibrillation
by: Mouhammad Rida Almouwannes, et al.
Published: (2025-08-01)